AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 87_CD 9Tangible_JJ fixed_JJ assets_NNS Assets_NNS in_IN Total_JJ Land_NN and_CC Plant_NN and_CC course_NN of_IN tangible_JJ buildings_NNS equipment_NN construction_NN assets_NNS $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN beginning_NN of_IN year_NN 4,128_CD 7,964_CD 948_CD 13,040_CD Capital_NN expenditure_NN 17 195 851_CD 1,063_CD Transfer_NNP of_IN assets_NNS into_IN use_NN 430_CD 641_CD 1,071_CD Disposals_NNS and_CC other_JJ movements_NNS 55_CD 329_CD 6_CD 390_CD Exchange_NNP adjustments_NNS 281_CD 589_CD 45_CD 915_CD At_IN end_NN of_IN year_NN 4,801_CD 9,060_CD 767_CD 14,628_CD Depreciation_NN At_IN beginning_NN of_IN year_NN 1,139_CD 4,365_CD 5,504_CD Charge_NNP for_IN year_NN 172 744 916_CD Impairment_NNP 31_CD 31_CD Disposals_NNS and_CC other_JJ movements_NNS 37 299 336_CD Exchange_NNP adjustments_NNS 86 344 430_CD At_IN end_NN of_IN year_NN 1,360_CD 5,185_CD 6,545_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2004_CD 3,441_CD 3,875_CD 767_CD 8,083_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 2,989_CD 3,599_CD 948_CD 7,536_CD The_DT impairment_NN charge_NN in_IN the_DT year_NN was_VBD made_VBN to_TO write_VB off_RP assets_NNS associated_VBN with_IN Iressa_NNP ._.
Capital_NNP expenditure_NN in_IN the_DT year_NN of_IN $_$ 1,063_CD m_NN 2003_CD $_$ 1,239_CD m_NN did_VBD not_RB include_VB any_DT capitalized_VBN finance_NN leases_NNS 2003_CD $_$ nil_JJ ._.
Cash_NN expenditure_NN on_IN tangible_JJ fixed_JJ assets_NNS was_VBD $_$ 1,063_CD m_NN 2003_CD $_$ 1,282_CD m_NN ,_, 2002_CD $_$ 1,340_CD m._NN 2004_CD 2003_CD $_$ m_CD $_$ m_CD The_DT net_JJ book_NN value_NN of_IN land_NN and_CC buildings_NNS comprised_VBD Freeholds_NNP 3,434_CD 2,988_CD Short_JJ leases_NNS 7_CD 1_CD 3,441_CD 2,989_CD
